What are the side effects of Olaparib?

Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian cancer, breast cancer, pancreatic cancer and prostate cancer. Olaparib is a selective and potent inhibitor of the poly(ADP-ribose) polymerase (PARP) enzymes PARP1 and PARP2. PARPinhibitors represent a new class of anticancer therapies that work by exploiting defects in DNA repair and inducing cell death in cancer cells harboring BRCA mutations. Olaparib was first approved by the FDA and the European Union in December 2014, and was approved by Health Canada in April 2016.

Olaparib(Olaparib)What are the side effects?

The most common adverse reactions in clinical trials (≥10%):

As a single agent are nausea, fatigue (including asthenia), anemia, vomiting, diarrhea, decreased appetite, headache, dysgeusia, cough, neutropenia, dyspnea, dizziness, dyspepsia, leukopenia, and thrombocytopenia.

Concomitant use with bevacizumab includes nausea, fatigue (including asthenia), anemia, lymphopenia, vomiting, diarrhea, neutropenia, leukopenia, urinary tract infection, and headache.

Anemia, fatigue, nausea, diarrhea, decreased appetite, lymphopenia, dizziness, and abdominal pain may occur when combined with abiraterone and prednisone or prednisolone. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.